<turbo-stream action="append" target="audio_clips_list"><template>
    <hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8922289-the-biopharm-brief-alzheimer-s-advances-bispecific-innovation-and-a-new-ted-therapy"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Alzheimer&#39;s Advances, Bispecific Innovation, and a New TED Therapy
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Eisai highlights next-generation Alzheimer&#39;s research, Talawar Therapeutics secures $285 million to advance a first-in-class bispecific antibody, and the FDA approves a new biologic for thyroid eye disease.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1782764629" data-format="short_date">Jun 29</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8920132-the-biopharm-brief-fibrosis-bispecific-adcs-and-billion-dollar-deals"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Fibrosis, Bispecific ADCs, and Billion-Dollar Deals
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
This episode explores a first-in-class antibody entering the clinic for kidney fibrosis, the world&#39;s first approved bispecific ADC, and a major acquisition that strengthens AbbVie&#39;s immunology pipeline.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1782253765" data-format="short_date">Jun 23</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8919651-the-biopharm-brief-triple-threats-tl1a-bets-and-ai-brains"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Triple Threats, TL1A Bets, and AI Brains
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Innovent advances a trispecific antibody into Phase 3 multiple myeloma testing, Bionyra enters the crowded TL1A race in inflammatory bowel disease, and Insilico Medicine partners with SK Biopharmaceuticals to apply AI to neuroimmune and CNS drug discovery.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
3m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1782166228" data-format="short_date">Jun 22</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
3m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8918405-the-biopharm-brief-fda-decisions-vaccine-momentum-and-lymphoma-advances"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: FDA Decisions, Vaccine Momentum, and Lymphoma Advances
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Today&#39;s BioPharm Brief covers an FDA filing acceptance for Roche&#39;s Lunsumio and Polivy combination in lymphoma, a pediatric expansion for Merck&#39;s CAPVAXIVE vaccine, and a key advisory committee meeting for Moderna&#39;s mRNA-based flu vaccine.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1781820945" data-format="short_date">Jun 18</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8917469-the-biopharm-brief-dual-targets-treg-therapy-tumor-responses"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Dual Targets, Treg Therapy, Tumor Responses
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Early clinical data highlight advances in bispecific antibodies and immune modulation, with new findings in Type 2 inflammatory diseases, alopecia areata, and platinum-resistant ovarian cancer.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
3m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1781643875" data-format="short_date">Jun 16</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
3m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8916108-the-biopharm-brief-hormones-metabolism-momentum"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Hormones, Metabolism, Momentum
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
New clinical data highlight advances in endocrine, metabolic, and rare disease drug development, with positive updates from MBX Biosciences, Gan &amp; Lee Pharmaceuticals, and Novartis.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1781294499" data-format="short_date">Jun 12</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8915670-the-biopharm-brief-car-t-progress-adc-momentum-biosimilar-expansion"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: CAR-T Progress, ADC Momentum, Biosimilar Expansion
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
New developments in CAR-T cell therapy, antibody-drug conjugates, and biosimilars highlight continued innovation across oncology and immunology.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1781210504" data-format="short_date">Jun 11</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8915183-biopharm-brief-dermatology-neurology-and-oncology-updates"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
BioPharm Brief: Dermatology, Neurology, and Oncology Updates
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
This week&#39;s BioPharm Brief covers the FDA&#39;s approval of every-eight-week maintenance dosing for lebrikizumab in atopic dermatitis, Sanofi&#39;s decision to halt a Phase 3 CIDP study of riliprubart after a futility analysis, and new mogamulizumab data being presented at WCCL 2026 in cutaneous T-cell lymphoma.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1781137868" data-format="short_date">Jun 11</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8914645-biopharm-brief-rnai-obesity-and-diabetes-advances"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
BioPharm Brief: RNAi, Obesity, and Diabetes Advances
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
This week&#39;s BioPharm Brief highlights City Therapeutics&#39; efforts to advance its RNAi pipeline with a new financing round, positive Phase 3 data for survodutide in obesity and MASLD, and Lilly&#39;s oral GLP-1 Foundayo outperforming oral semaglutide in a landmark head-to-head type 2 diabetes trial.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1781045376" data-format="short_date">Jun 09</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8914172-the-biopharm-brief-myeloma-hemophilia-and-kras"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Myeloma, Hemophilia, and KRAS
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Sanofi secured European approval for a subcutaneous formulation of Sarclisa in multiple myeloma, Pfizer expanded HYMPAVZI&#39;s FDA-approved use in hemophilia, and Johnson &amp; Johnson agreed to acquire Firefly Bio to strengthen its KRAS-focused oncology pipeline.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1780972162" data-format="short_date">Jun 09</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8913033-the-biopharm-brief-biosimilars-stem-cells-and-checkpoints"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Biosimilars, Stem Cells, and Checkpoints
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In this episode of The BioPharm Brief, we cover the FDA approval of Lupin&#39;s interchangeable ranibizumab biosimilar Ranluspec, a new iPSC cell therapy manufacturing partnership between Made Scientific and Pluristyx, and emerging research on TIGIT as a potential immunotherapy target in pancreatic cancer. 
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
3m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1780681656" data-format="short_date">Jun 05</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
3m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8912401-the-biopharm-brief-breakthroughs-bispecifics-and-biosimilars"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Breakthroughs, Bispecifics, and Biosimilars
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Today&#39;s biopharmaceutical news highlights an FDA breakthrough designation in spinal muscular atrophy, an expanded oncology collaboration focused on tumor activated bispecifics, and a new biosimilar launch for retinal diseases in Europe.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1780594977" data-format="short_date">Jun 04</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8911532-the-biopharm-brief-rna-editing-cardiac-remodeling-rare-disease-gene-therapy"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: RNA Editing, Cardiac Remodeling, Rare Disease Gene Therapy
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Daily biopharma update covering RNA exon editing licensing, gene therapy clinical data, and preclinical rare disease collaboration advances across the biotech sector.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1780513758" data-format="short_date">Jun 03</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8911087-the-biopharm-brief-gene-therapy-reform-cancer-trial-endpoints-and-a-1-2b-rare-disease-deal"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Gene Therapy Reform, Cancer Trial Endpoints, and a $1.2B Rare Disease Deal
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Today’s BioPharm Brief covers FDA draft guidance aimed at streamlining rare disease gene therapy development, Phase 3 trial updates involving dual survival endpoints in oncology programs, and Eli Lilly’s $1.2 billion licensing deal for a GLP-2 therapy in short bowel syndrome.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1780437052" data-format="short_date">Jun 02</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8910484-the-biopharm-brief-smarter-immunotherapy-stronger-responses-longer-survival"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Smarter Immunotherapy, Stronger Responses, Longer Survival
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
New data in lung cancer and solid tumors highlight the growing impact of next-generation immunotherapies, including bispecific antibodies and TCR-based therapies, as developers report encouraging efficacy across difficult-to-treat patient populations.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
1m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1780346295" data-format="short_date">Jun 01</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
1m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8909625-the-biopharm-brief-billion-dollar-bet-smarter-immunotherapy-hepatitis-b-hope"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Billion-Dollar Bet, Smarter Immunotherapy, Hepatitis B Hope
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Pfizer’s $10.5 billion oncology collaboration with Innovent, early clinical progress for a novel PD-1/IL-2 fusion protein, and promising Phase III hepatitis B cure data highlight today’s key developments in biopharmaceutical innovation.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1780088977" data-format="short_date">May 29</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8908620-the-biopharm-brief-dermatology-data-and-autoimmune-innovation"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Dermatology Data and Autoimmune Innovation
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Olezarsen’s latest pancreatitis data, Apogee’s advancing atopic dermatitis program, and Jade Biosciences’ first-in-human autoimmune trial highlight continued momentum in RNA therapeutics, immunology, and antibody development across the biopharmaceutical industry.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1779911583" data-format="short_date">May 27</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8908201-the-biopharm-brief-gene-editing-myeloma-neuroregeneration"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Gene Editing, Myeloma, Neuroregeneration
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Today’s BioPharm Brief covers promising Phase 1 data for Eli Lilly’s gene-editing therapy VERVE-102, evolving CAR-T and bispecific competition in multiple myeloma, and new preclinical findings for a Parkinson’s disease regenerative therapy candidate.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1779831387" data-format="short_date">May 26</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8907067-the-biopharm-brief-oncology-growth-validation"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Oncology, Growth, Validation
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Today’s BioPharm Brief covers major developments in oncology, rare disease therapeutics, and ADC manufacturing, including positive Phase 3 data for Kelun-Biotech’s sac-TMT in triple-negative breast cancer, promising hypochondroplasia results for vosoritide, and new perspectives on risk-based cleaning validation for highly potent drug manufacturing.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1779481570" data-format="short_date">May 22</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8906694-the-biopharm-brief-weight-loss-oncology-longevity"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Weight Loss, Oncology, Longevity
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
This edition of The BioPharm Brief highlights major advances in obesity, oncology, and regenerative medicine, including Merck’s Phase 3 ADC study in metastatic colorectal cancer, Eli Lilly’s promising retatrutide obesity trial results, and manufacturing progress supporting Klotho cell therapy development. Together, these updates reflect the biopharma industry’s accelerating focus on targeted th...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1779407933" data-format="short_date">May 21</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8906054-the-biopharm-brief-rna-editing-liver-safety-joint-gains"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
4: The BioPharm Brief: RNA Editing, Liver Safety, Joint Gains
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
New clinical trial updates highlight advances in RNA editing for alpha-1 antitrypsin deficiency, semaglutide data in MASH liver disease, and improved joint outcomes in psoriatic arthritis treatment comparisons.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
3m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1779310255" data-format="short_date">May 20</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
3m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8905601-the-biopharm-brief-smarter-platforms-safer-therapies-ai-acceleration"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
3: The BioPharm Brief: Smarter Platforms, Safer Therapies, AI Acceleration
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
oday’s BioPharm Brief covers how biopharma companies are leveraging next-generation platform technologies—from CNS-targeted gene therapy and AI-driven R&amp;D to antibody-cleaving biologics partnerships—to improve therapeutic precision, reduce development barriers, and expand access to advanced medicines.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
3m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1779226806" data-format="short_date">May 19</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
3m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8905057-the-biopharm-brief-adc-expansion-early-breast-cancer-biosimilar-momentum"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
2: The BioPharm Brief: ADC Expansion, Early Breast Cancer, Biosimilar Momentum
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Today’s BioPharm Brief covers major developments in antibody-drug conjugates, early-stage HER2-positive breast cancer treatment, and the expanding biosimilars market.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1779135649" data-format="short_date">May 18</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8904264-the-biopharm-brief-oncology-momentum-car-t-advances-strategic-expansion"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
1: The BioPharm Brief: Oncology Momentum, CAR-T Advances, Strategic Expansion
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
AstraZeneca reported encouraging bladder cancer data for Imfinzi plus BCG, Imviva shared early remission findings for allogeneic CAR-T therapy in lupus, and Biogen expanded its rare disease pipeline through its acquisition of Apellis Pharmaceuticals.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1778878776" data-format="short_date">May 15</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8903728-the-biopharm-brief-immunotherapy-wins-next-gen-car-t-and-hope-for-duchenne-patients"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Immunotherapy Wins, Next-Gen CAR-T, and Hope for Duchenne Patients
</h5>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1778789000" data-format="short_date">May 14</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8902544-the-biopharm-brief-gene-therapy-adcs-big-pharma-alliances"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Gene Therapy, ADCs, Big Pharma Alliances
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Today’s BioPharm Brief highlights a new gene therapy trial in Pompe disease, an FDA Breakthrough Therapy designation for a B7-H4 ADC in adenoid cystic carcinoma, and a major $15.2 billion BMS–Hengrui collaboration spanning oncology, hematology, and immunology.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
3m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1778603769" data-format="short_date">May 12</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
3m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8902222-the-biopharm-brief-precision-medicine-expansion-accelerates-autoimmune-and-targeted-oncology-dev"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Precision Medicine Expansion Accelerates Autoimmune and Targeted Oncology Development
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, regulatory progress, and precision medicine innovation. Today’s update highlights expanding treatment access in autoimmune disease, accelerated development pathways for targeted oncology therapies, and a new approval in fusion-driven cancer care.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
3m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1778536736" data-format="short_date">May 11</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
3m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8901371-the-biopharm-brief-bispecifics-biocatalysis-and-dual-pathway-therapies"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Bispecifics, Biocatalysis, and Dual-Pathway Therapies
</h5>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1778279297" data-format="short_date">May 08</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8901368-the-biopharm-brief-bispecifics-biocatalysis-and-dual-pathway-therapies"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Bispecifics, Biocatalysis, and Dual-Pathway Therapies
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Today’s BioPharm Brief covers next-generation immunotherapy, scalable peptide manufacturing, and Johnson &amp; Johnson’s dual-pathway approach to inflammatory bowel disease treatment.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1778278674" data-format="short_date">May 08</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8901358-the-biopharm-brief-bispecifics-biocatalysis-and-dual-pathway-therapies"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Bispecifics, Biocatalysis, and Dual-Pathway Therapies
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Today’s BioPharm Brief covers next-generation immunotherapy, scalable peptide manufacturing, and Johnson &amp; Johnson’s dual-pathway approach to inflammatory bowel disease treatment.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1778277040" data-format="short_date">May 08</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8900778-the-biopharm-brief-breakthrough-signals-in-cancer-duchenne-and-rna-medicine"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Breakthrough Signals in Cancer, Duchenne, and RNA Medicine
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Today’s BioPharm Brief covers promising AML remission data from Aptevo, encouraging Duchenne muscular dystrophy trial results from Entrada Therapeutics, and a new GSK licensing deal expanding cardiometabolic RNA therapy development.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1778182976" data-format="short_date">May 07</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8900306-the-biopharm-brief-precision-immunotherapy-expansion"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Precision, Immunotherapy, Expansion
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Biopharma news today highlights precision MASH therapies, emerging immuno-oncology platforms, and major U.S. manufacturing investments reshaping drug development and supply chains.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1778101042" data-format="short_date">May 06</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8899542-the-biopharm-brief-breakthrough-biologics-and-long-term-wins-in-ibd-and-beyond"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Breakthrough Biologics and Long-Term Wins in IBD and Beyond
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Phase III data in thyroid eye disease, long-term ulcerative colitis outcomes, and Crohn disease advances highlight continued momentum in biologics and immunology innovation.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1778001501" data-format="short_date">May 05</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8899169-the-biopharm-brief-breakthroughs-buyouts-and-biologics"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Breakthroughs, Buyouts, and Biologics
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
FDA approvals, biotech acquisitions, and clinical trial updates are shaping today’s biopharma landscape. This episode of The BioPharm Brief covers the first approved PROTAC therapy for breast cancer, UCB’s planned acquisition of Candid Therapeutics, and new clinical data from Takeda Pharmaceutical Company in primary immunodeficiency.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1777928867" data-format="short_date">May 04</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8898221-the-biopharm-brief-microbiome-fast-track-leo-pharma-gene-therapy-deal-aav-automation-advances"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The Biopharm Brief: Microbiome Fast Track, Leo Pharma Gene Therapy Deal, AAV Automation Advances
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Microbiome therapies gain FDA Fast Track status, Leo Pharma expands into gene therapy via acquisition, and automation improves AAV manufacturing efficiency.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1777669433" data-format="short_date">May 01</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8897734-the-biopharm-brief-metabolic-phase-iii-progress-her2-oncology-momentum-and-us-manufacturing-ex"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Metabolic Phase III Progress, HER2 Oncology Momentum, and US Manufacturing Expansion Drive Industry Scale
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, regulatory progress, and global manufacturing strategy. Today’s update highlights advances in metabolic disease, oncology regulatory momentum, and continued investment in US-based drug production infrastructure.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1777582981" data-format="short_date">Apr 30</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8897227-the-biopharm-brief-biosimilar-approval-elrexfio-data-sox2-innovation"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Biosimilar Approval, Elrexfio Data, SOX2 Innovation
</h5>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1777498038" data-format="short_date">Apr 29</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8896706-the-biopharm-brief-survodutide-data-orca-q-rmat-ligand-deal"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Survodutide Data, Orca-Q RMAT, Ligand Deal
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Survodutide delivers significant Phase III weight loss results, FDA grants RMAT status to Orca-Q, and Ligand expands its portfolio with a $739 million acquisition of XOMA.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1777411567" data-format="short_date">Apr 28</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8896262-the-biopharm-brief-fda-advances-autoimmune-pipeline-with-new-delivery-options-and-priority-review"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: FDA Advances Autoimmune Pipeline with New Delivery Options and Priority Review
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
The BioPharm Brief covers three recent FDA developments shaping the autoimmune and inflammatory disease landscape. The agency cleared a subcutaneous autoinjector for anifrolumab in systemic lupus erythematosus, enabling at-home administration. It also granted Priority Review to nipocalimab for warm autoimmune hemolytic anemia, highlighting its potential as a targeted treatment for a rare condit...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1777329893" data-format="short_date">Apr 27</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8895276-the-biopharm-brief-innovation-gene-therapy-momentum-and-next-gen-adcs-lead-today-s-headlines"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Innovation, Gene Therapy Momentum, and Next-Gen ADCs Lead Today’s Headlines
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
This episode of The BioPharm Brief covers innovation trends in biopharma hubs, a positive CHMP opinion for Novartis’ intrathecal gene therapy in spinal muscular atrophy, and early clinical data for a novel bispecific ADC in breast cancer. Key updates highlight regulatory momentum, emerging technologies, and next-generation oncology therapeutics.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1777059553" data-format="short_date">Apr 24</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8894697-the-biopharm-brief-car-t-advances-pediatric-biologic-approval-and-oral-glp-1-progress"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: CAR-T Advances, Pediatric Biologic Approval, and Oral GLP-1 Progress
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
New developments in CAR-T therapy, pediatric biologics, and oral GLP-1 treatments highlight expanding innovation across oncology, immunology, and metabolic disease. Early data and regulatory progress signal a shift toward more targeted and accessible therapies for underserved patient populations.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1776968413" data-format="short_date">Apr 23</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8894287-the-biopharm-brief-early-design-risks-oncology-signals-and-a-biosimilars-power-move"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
This episode of The BioPharm Brief covers three key developments shaping today’s biopharmaceutical landscape, with a focus on cell and gene therapy manufacturing, oncology drug development, and biosimilars market strategy. Experts highlight how early process design and CMC planning are critical to the success of advanced therapies, helping companies avoid costly delays and scale-up challenges. ...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1776889355" data-format="short_date">Apr 22</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8893679-the-biopharm-brief-ai-immunology-and-regulatory-momentum"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: AI, Immunology, and Regulatory Momentum
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
AstraZeneca reported consistent Phase III results for its IL-33 biologic in COPD, while Boehringer Ingelheim continues expanding its use of AI to accelerate drug discovery and disease research. Meanwhile, the U.S. Food and Drug Administration has accepted a biologics license application for Gazyva as a potential treatment for systemic lupus erythematosus, signaling progress in addressing unmet ...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1776801660" data-format="short_date">Apr 21</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8893082-the-biopharm-brief-oncology-innovations-continue-with-durable-survival-in-vivo-car-t-and-combi"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Oncology Innovations Continue with Durable Survival, In Vivo CAR-T, and Combination Therapies
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, clinical progress, and regulatory strategy. Today’s update highlights advances in oncology across rare cancers, immunotherapy combinations, and strategic acquisitions aimed at next-generation cell therapy platforms.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1776715592" data-format="short_date">Apr 20</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8891301-bp-march-april-promo"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
BP March April Promo
</h5>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
43s
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1776432975" data-format="short_date">Apr 17</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
43s
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8880737-the-biopharm-brief-talking-lifecycle-optimization-strategic-investment-and-collaboration-shapi"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Talking Lifecycle Optimization, Strategic Investment, and Collaboration Shaping Growth Trajectory
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Welcome to The BioPharm Brief, your daily snapshot of the developments shaping biopharmaceutical research, regulatory progress, and industry strategy. Today’s update highlights a regulatory milestone in neuromuscular disease alongside broader industry perspectives on innovation, investment, and collaboration driving long-term growth.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1774905374" data-format="short_date">Mar 30</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8878318-the-biopharm-brief-what-s-the-big-deal-about-multispecific-t-cell-engagers-in-cancer-and-autoimm"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Welcome to The BioPharm Brief, your daily snapshot of key developments shaping biopharmaceutical innovation and clinical strategy. Today’s update highlights continued momentum in next-generation T-cell engager platforms, driven by both early-stage financing and large biopharma partnerships targeting complex diseases.
First, Excalipoint Therapeutics has launched with $68.7 million in seed financ...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1774382661" data-format="short_date">Mar 24</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8876246-the-biopharm-brief-investments-in-next-gen-modalities-drive-oncology-and-metabolic-therapy-devel"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Investments in Next-Gen Modalities Drive Oncology and Metabolic Therapy Development
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Welcome to The BioPharm Brief, your daily snapshot of key developments in biopharmaceutical research, innovation, and clinical progress. Today’s update highlights fresh funding for T‑cell engager platforms and continued momentum in multi‑agonist metabolic therapy development.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1773945959" data-format="short_date">Mar 19</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8874701-the-biopharm-brief-il-23-pathway-expansion-signals-next-wave-of-immunology-lifecycle-development"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: IL-23 Pathway Expansion Signals Next Wave of Immunology Lifecycle Development
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Welcome to The BioPharm Brief, your daily snapshot of the developments shaping biopharmaceutical research, regulatory progress, and clinical innovation. Today’s update focuses on a regulatory milestone that could further expand treatment options for patients living with psoriatic arthritis.
In the United States, FDA has accepted for review a supplemental biologics license application for tildra...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1773691939" data-format="short_date">Mar 16</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8871658-the-biopharm-brief-fda-priority-review-and-trispecific-antibodies-advance-precision-oncology"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43521810/75x75/c 75w, https://audioboom.com/i/43521810/150x150/c 150w, https://audioboom.com/i/43521810/300x300/c 300w, https://audioboom.com/i/43521810/600x600/c 600w, https://audioboom.com/i/43521810/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43521810/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: FDA Priority Review and Trispecific Antibodies Advance Precision Oncology
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research and clinical innovation. Today’s podcast highlights advances in targeted oncology therapies, from antibody‑drug conjugates, or ADCs, to next‑generation multispecific antibodies, and how these innovations are moving through regulatory and clinical pathways.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1773087385" data-format="short_date">Mar 09</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>

</template></turbo-stream>
  <turbo-stream action="replace" target="turbo_pagination"><template><turbo-frame loading="lazy" id="turbo_pagination" src="/channels/5167274.turbo_stream?list=1&amp;page=3"><div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div class="visually-hidden">
<a href="/channels/5167274?list=1&amp;page=3">next page</a>
</div>
</turbo-frame></template></turbo-stream>
